|
Title
|
|
|
|
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Cardiovascular adverse events induced by immune checkpoint inhibitors (ICIs) have gained significant interest over the past decade due to their impact on short- and long-term outcomes. They were initially thought to be rare, but the increasing use of ICIs in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in their incidence. Different guidelines have proposed screening measures for ICI-induced myocarditis by incorporating troponin measurements at baseline and during the first few weeks of treatment. However, no specific guidelines have been developed yet regarding the interpretation of an asymptomatic rise in troponins. This state-of-the art review aims to provide an overview of the clinical relevance of elevated troponins during checkpoint inhibition and recommendations on how to manage elevated troponin levels during ICI therapy. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
ESMO Open / European Society for Medical Oncology.
|
|
|
Publication
|
|
|
|
Amsterdam
:
Elsevier
,
2021
|
|
|
ISSN
|
|
|
|
2059-7029
|
|
|
DOI
|
|
|
|
10.1016/J.ESMOOP.2021.100216
|
|
|
Volume/pages
|
|
|
|
6
:4
(2021)
, 9 p.
|
|
|
Article Reference
|
|
|
|
100216
|
|
|
ISI
|
|
|
|
000703610200042
|
|
|
Pubmed ID
|
|
|
|
34271309
|
|
|
Medium
|
|
|
|
E-only publicatie
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|